#news #biotech Bristol Myers’ deucravacitinib beats out exiled Otezla, eyes 2022 launch

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Bristol Myers’ deucravacitinib beats out exiled Otezla, eyes 2022 launch .Bristol Myers’ deucravacitinib beats out exiled Otezla, eyes 2022 launch
badams
Fri, 04/23/2021 – 04:26

from FierceBiotech: Biotech https://ift.tt/3eovRXv